NxStage Medical surges nearly 8% after beating Wall Street

February 28, 2013 by Brad Perriello

NxStage Medical tops Wall Street's forecasts for both sales and losses, sending share prices up nearly 8% today.

NxStage  press release

NxStage Medical (NSDQ:NXTM) shares jumped nearly 8% today after the medical device company reported Wall-Street-beating results for the 4th quarter and 2012.

The Lawrence, Mass.-based medical device company said it pared its 4th-quarter losses by nearly 50%, to $2.4 million or 4¢ per share, on sales of $65.0 million for the 3 months ended Dec. 31, 2012. That amounts to top-line growth of 14.0% compared with Q4 2011.

For the full year, NxStage said losses were $14.6 million or 26¢ per share, down 32.2% compared with 2011.

Sign up to get our free newsletters delivered straight to your inbox

The home hemodialysis company beat The Street's consensus earnings forecast by a penny during both Q4 and 2012 and topped analysts' sales prediction of $63.5 million. NXTM shares surged on the news, opening up $3.2% at $11.20 apiece, peaking at $11.68 (up 7.6%) before subsiding to $11.38 as of about 11:30 a.m. today, up 4.9%.